论文部分内容阅读
目的探讨自体外周血造血干细胞移植(APBSCT)治疗多发性骨髓瘤(MM)的疗效。方法该院自2006年12月至2011年10月,对18例MM患者,采用化疗联合粒细胞集落刺激因子(G-CSF)动员造血干细胞,以口服或静脉注射美法仑预处理后行APBSCT治疗,并评价其疗效。结果 17例患者移植成功,1例植入失败。移植后随访3～60个月,13例获得完全缓解(CR),6例CR后复发,复发患者中1例经万珂治疗后再次获得CR。1例患者行2次移植达到非常好的部分缓解(VGPR)。结论 MM患者行APBSCT安全有效且耐受性好。移植后维持治疗对于延长无事件生存期(EFS)及总生存期(OS)具有重要意义。
Objective To investigate the efficacy of autologous peripheral blood stem cell transplantation (APBSCT) in the treatment of multiple myeloma (MM). Methods From December 2006 to October 2011, 18 patients with MM were treated with chemotherapy combined with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells and pretreated with oral or intravenous melphalan APBSCT Treatment, and evaluate its efficacy. Results 17 patients were successfully transplanted and 1 patient failed to implant. All cases were followed up for 3 to 60 months after transplantation. Complete remission (CR) was achieved in 13 cases and relapsed in 6 cases after CR. One case of recurrent patients was again treated with vancomycin. One patient underwent 2 grafts to achieve very good partial response (VGPR). Conclusion MM patients with APBSCT safe and effective and well tolerated. Post-transplant maintenance therapy is important for prolonging event-free survival (EFS) and overall survival (OS).